MDACC Study No:NABTC04-03 ( NCT No: NCT00268385)
Title:A Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid {SAHA}) in Combination with Temozolomide in Patients with Malignant Gliomas.
Principal Investigator:John DeGroot
Treatment Agent:Vorinostat
Study Status:Terminated
Study Description:The goal of this clinical study is to find the highest tolerated dose of
vorinostat (SAHA) that can be given in combination with temozolomide, without
causing severe side effects in most patients with malignant glioma.
Hide details for General InformationGeneral Information

Disease Group:Brain; CNS
Phase of Study:Phase I
Treatment Agents:Vorinostat
Treatment Location:MDACC + Community Programs (CCOP/Network)
Estimated Length of Stay in Houston:None
Supported By:N/A
Return Visit:Every 4 weeks
Home Care:Vorinostat (SAHA) and Temozolomide will both be taken at home. Vorinostat will
be taken with food bid. Temozolomide will be taken on an empty stomach two
hours after food and the dose of vorinostat or one hour before eating.

Hide details for Study Contact InformationStudy Contact Information

Physician Name:John DeGroot
Dept:Neuro Oncology
For Clinical Trial Enrollment:713-792-2883
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults